NASDAQ:CNAT - Conatus Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.62 +0.12 (+8.00 %) (As of 12/12/2018 08:00 AM ET)Previous Close$1.50Today's Range$1.53 - $1.7552-Week Range$1.49 - $7.95Volume1.73 million shsAverage Volume659,372 shsMarket Capitalization$51.75 millionP/E Ratio-2.64Dividend YieldN/ABeta1.99 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company has collaboration agreement with Novartis to conduct three Phase IIb clinical trials Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California. Receive CNAT News and Ratings via Email Sign-up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CNAT Previous Symbol CUSIPN/A Webwww.conatuspharma.com Phone858-376-2600 Debt Debt-to-Equity Ratio0.83 Current Ratio2.39 Quick Ratio2.39 Price-To-Earnings Trailing P/E Ratio-2.64 Forward P/E Ratio-2.66 P/E GrowthN/A Sales & Book Value Annual Sales$35.38 million Price / Sales1.39 Cash FlowN/A Price / Cash FlowN/A Book Value$0.93 per share Price / Book1.74 Profitability EPS (Most Recent Fiscal Year)($0.61) Net Income$-17,390,000.00 Net Margins-52.77% Return on Equity-83.99% Return on Assets-26.03% Miscellaneous Employees35 Outstanding Shares30,260,000Market Cap$51.75 million OptionableOptionable Conatus Pharmaceuticals (NASDAQ:CNAT) Frequently Asked Questions What is Conatus Pharmaceuticals' stock symbol? Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT." How were Conatus Pharmaceuticals' earnings last quarter? Conatus Pharmaceuticals Inc (NASDAQ:CNAT) posted its earnings results on Thursday, November, 1st. The biotechnology company reported ($0.15) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.15). The biotechnology company had revenue of $7.67 million for the quarter, compared to the consensus estimate of $9.70 million. Conatus Pharmaceuticals had a negative net margin of 52.77% and a negative return on equity of 83.99%. View Conatus Pharmaceuticals' Earnings History. When is Conatus Pharmaceuticals' next earnings date? Conatus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 6th 2019. View Earnings Estimates for Conatus Pharmaceuticals. What price target have analysts set for CNAT? 5 brokerages have issued twelve-month price targets for Conatus Pharmaceuticals' stock. Their forecasts range from $4.00 to $20.00. On average, they anticipate Conatus Pharmaceuticals' stock price to reach $11.1150 in the next year. This suggests a possible upside of 586.1% from the stock's current price. View Analyst Price Targets for Conatus Pharmaceuticals. What is the consensus analysts' recommendation for Conatus Pharmaceuticals? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Conatus Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Conatus Pharmaceuticals. Has Conatus Pharmaceuticals been receiving favorable news coverage? News articles about CNAT stock have been trending positive on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Conatus Pharmaceuticals earned a media sentiment score of 2.6 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the stock's share price in the immediate future. Who are some of Conatus Pharmaceuticals' key competitors? Some companies that are related to Conatus Pharmaceuticals include Urovant Sciences (UROV), Aquestive Therapeutics (AQST), Kamada (KMDA), Galectin Therapeutics (GALT), Synlogic (SYBX), LifeVantage (LFVN), Taiwan Liposome (TLC), Newron Pharmaceuticals (NWPHF), Acer Therapeutics (ACER), Kala Pharmaceuticals (KALA), Zafgen (ZFGN), Aeglea Bio Therapeutics (AGLE), Calithera Biosciences (CALA), Xenon Pharmaceuticals (XENE) and MEI Pharma (MEIP). Who are Conatus Pharmaceuticals' key executives? Conatus Pharmaceuticals' management team includes the folowing people: Dr. Steven J. Mento, Co-Founder, Pres, CEO & Director (Age 66)Dr. Keith W. Marshall MBA, Ph.D., Exec. VP, COO & CFO (Age 50)Dr. David T. Hagerty, Exec. VP of Clinical Devel. (Age 63)Dr. Alfred P. Spada, Co-Founder, Exec. VP of R&D and Chief Scientific Officer (Age 60)Mr. Alan R. Engbring, Exec. Director of Investor Relations & Corp. Communications Who are Conatus Pharmaceuticals' major shareholders? Conatus Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.37%), Sofinnova Ventures Inc (1.78%), Artal Group S.A. (1.65%), Acadian Asset Management LLC (0.60%), Alambic Investment Management L.P. (0.17%) and Virtu Financial LLC (0.09%). View Institutional Ownership Trends for Conatus Pharmaceuticals. Which major investors are selling Conatus Pharmaceuticals stock? CNAT stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, Alambic Investment Management L.P. and Acadian Asset Management LLC. View Insider Buying and Selling for Conatus Pharmaceuticals. Which major investors are buying Conatus Pharmaceuticals stock? CNAT stock was purchased by a variety of institutional investors in the last quarter, including Artal Group S.A., BlackRock Inc. and Virtu Financial LLC. View Insider Buying and Selling for Conatus Pharmaceuticals. How do I buy shares of Conatus Pharmaceuticals? Shares of CNAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Conatus Pharmaceuticals' stock price today? One share of CNAT stock can currently be purchased for approximately $1.62. How big of a company is Conatus Pharmaceuticals? Conatus Pharmaceuticals has a market capitalization of $51.75 million and generates $35.38 million in revenue each year. The biotechnology company earns $-17,390,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. Conatus Pharmaceuticals employs 35 workers across the globe. What is Conatus Pharmaceuticals' official website? The official website for Conatus Pharmaceuticals is http://www.conatuspharma.com. How can I contact Conatus Pharmaceuticals? Conatus Pharmaceuticals' mailing address is 16745 WEST BERNARDO DRIVE Suite 200, San Diego CA, 92127. The biotechnology company can be reached via phone at 858-376-2600 or via email at [email protected] MarketBeat Community Rating for Conatus Pharmaceuticals (NASDAQ CNAT)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 380 (Vote Outperform)Underperform Votes: 199 (Vote Underperform)Total Votes: 579MarketBeat's community ratings are surveys of what our community members think about Conatus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNAT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/12/2018 by MarketBeat.com StaffFeatured Article: What is dollar cost averaging (DCA)?